Giant Cell Arteritis and Polymyalgia Rheumatica: an Update

Current Rheumatology Reports

Volumn 17, Issue 2, 2015, Pages

  González Gay, Miguel A ^a,b   Pina, Trinitario ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Aortitis; FDG PET; Giant cell arteritis; Polymyalgia rheumatica; Treatment

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; FLUORODEOXYGLUCOSE F 18; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; TOCILIZUMAB; GLUCOCORTICOID;

BLOOD VESSEL BIOPSY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DOPPLER ECHOGRAPHY; DRUG PULSE THERAPY; ETHNIC DIFFERENCE; GEOGRAPHIC DISTRIBUTION; GIANT CELL ARTERITIS; HUMAN; IMAGE GUIDED BIOPSY; INCIDENCE; INTRAVASCULAR ULTRASOUND; LOW BACK PAIN; MAGNETIC RESONANCE ANGIOGRAPHY; OUTCOME ASSESSMENT; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; REVIEW; RHEUMATIC POLYMYALGIA; TEMPORAL ARTERY; POLYMYALGIA RHEUMATICA; TREATMENT OUTCOME;

GIANT CELL ARTERITIS; GLUCOCORTICOIDS; HUMANS; POLYMYALGIA RHEUMATICA; TREATMENT OUTCOME;

EID: 84921475237     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-014-0480-1     Document Type: Review

References (50)

1. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy JA, Gonzalez-Juanatey C, Martin J, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61:1454–612.
2. Gonzalez-Gay MA. Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Semin Arthritis Rheum. 2004;33:289–93.
3. Gonzalez-Gay MA, Miranda-Filloy JA, Lopez-Diaz MJ, Perez-Alvarez R, Gonzalez-Juanatey C, Sanchez-Andrade A, et al. Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study. Medicine (Baltimore). 2007;86:61–88.
4. Petri H, Nevitt A, Sarsour K, Napalkov P, Collinson N. Incidence of giant cell arteritis and characteristics of patients: data-driven analysis of comorbidities. Arthritis Care Res (Hoboken). 2014. doi:10.1002/acr.22429. The incidence of GCA is higher in women, in particular in the 70 to 79 years old age group.
5. Dunstan E, Lester SL, Rischmueller M, Dodd T, Black R, Ahern M, et al. Epidemiology of biopsy-proven giant cell arteritis in South Australia. Intern Med J. 2014;44:32–9. Clinical features is Australian individuals with GCA is similar to that previously reported in Western countries.
6. Alba MA, Mena-Madrazo JA, Reyes E, Flores-Suárez LF. Giant cell arteritis in Mexican patients. J Clin Rheumatol. 2012;18:1–7. The incidence of GCA in Hispanic is low.
7. González-Gay MA, Amoli MM, Garcia-Porrua C, Ollier WE. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum. 2003;33:38–48.
8. Serrano A, Márquez A, Mackie SL, Carmona FD, Solans R, Miranda-Filloy JA, et al. Identification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis. Ann Rheum Dis. 2013;72:1882–6. PTPN22 R620W functional variant has been implicated in the susceptibility to several autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. The present study also confirms its implication in GCA. These findings indicate that PTPN22 may represent a common pathway for different autoimmune diseases.
9. Carmona FD, González-Gay MA, Martín J. Genetic component of giant cell arteritis. Rheumatology (Oxford). 2014;53:6–18. Besides the well-known association with genes located in the HLA region, other gene polymorphisms located outside this region also account for the susceptibility to GCA.
10. Weyand CM, Goronzy JJ. Arterial wall injury in giant cell arteritis. Arthritis Rheum. 1999;42:844.
11. Dejaco C, Duftner C, Al-Massad J, Wagner AD, Park JK, Fessler J, et al. NKG2D stimulated T-cell autoreactivity in giant cell arteritis and polymyalgia rheumatica. Ann Rheum Dis. 2013;72:1852–9. This study highlights the relevance of T cells and the implication of NKG2D in the pathogenesis of GCA and PMR.
12. Samson M, Audia S, Fraszczak J, Trad M, Ornetti P, Lakomy D, et al. Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum. 2012;64:3788–98. Although the suppressive activity of circulating Treg cells is not altered, the number of circulating Treg cells is decreased in patients with GCA or PMR. The numbers of Th17 lymphocytes are significantly increased in patients with GCA and PMR.
13. van der Geest KS, Abdulahad WH, Chalan P, Rutgers A, Horst G, Huitema MG, et al. Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica. Arthritis Rheumatol. 2014;66:1927–38. Patients newly diagnosed as having GCA or PMR exhibit decreased numbers of circulating B cells compared to healthy controls. B cell numbers recover following therapy in patients with GCA and PMR.
14. Gonzalez-Gay M. The diagnosis and management of patients with giant cell arteritis. J Rheumatol. 2005;32:1186–8.
15. Schmidt WA, Kraft HE, Vorpahl K, Volker L, Gromnica-Ihle EJ. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med. 1997;337:1336–42.
16. Arida A, Kyprianou M, Kanakis M, Sfikakis PP. The diagnostic value of ultrasonography-derived edema of the temporal artery wall in giant cell arteritis: a second meta-analysis. BMC Musculoskelet Disord. 2010;11:44.
17. Germanò G, Muratore F, Cimino L, Lo Gullo A, Possemato N, Macchioni P, et al. Is colour duplex sonography-guided temporal artery biopsy useful in the diagnosis of giant cell arteritis? A randomized study. Rheumatology (Oxford) 2014 Jun 17. pii: keu241. [Epub ahead of print] Interesting study that indicates that color duplex US of the temporal artery does not improve the sensitive of TAB to make a diagnosis of GCA. The results, rather than reducing the potential usefulness of color duplex US for the diagnosis of GCA, highlight the relevance of an adequate clinical examination to proceed to TAB when GCA is suspected.
18. Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, Gonzalez-Louzao C, Rodriguez-Ledo P. Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy. Semin Arthritis Rheum. 2001;30:249–56.
19. Cavazza A, Muratore F, Boiardi L, Restuccia G, Pipitone N, Pazzola G, et al. Inflamed temporal artery: histologic findings in 354 biopsies, with clinical correlations. Am J Surg Pathol. 2014;38:1360–70. Study on 322 temporal artery biopsies. It discloses the wide spectrum of inflammatory lesions found in TAB. It also confirmed that some conditions, in particular systemic vasculitides different from GCA, may cause inflammation of the temporal artery.
20. Sakellariou G, Iagnocco A, Riente L, Ceccarelli F, Carli L, Di Geso L, et al. Ultrasound imaging for the rheumatologist XLIII. Ultrasonographic evaluation of shoulders and hips in patients with polymyalgia rheumatica: a systematic literature review. Clin Exp Rheumatol. 2013;31:1–7. Very elegant review article that indicates that in patients with suggestive clinical features of PMR, a shoulder US, in particular when findings are bilateral, is useful to support a diagnosis of PMR.
21. Gonzalez-Gay MA, Garcia-Porrua C, Piñeiro A, Pego-Reigosa R, Llorca J, Hunder GG. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine (Baltimore). 2004;83:335–41.
22. Pipitone N, Versari A, Salvarani C. Role of imaging studies in the diagnosis and follow-up of large-vessel vasculitis: an update. Rheumatology (Oxford). 2008;47:403–8.
23. Puppo C, Massollo M, Paparo F, Camellino D, Piccardo A, Shoushtari Zadeh Naseri M, et al. Giant cell arteritis: a systematic review of the qualitative and semiquantitative methods to assess vasculitis with 18F-fluorodeoxyglucose positron emission tomography. Biomed Res Int. 2014;2014:574248. 18 F-FDG- PET is an effective tool for the diagnosis, grading, and follow-up of patients affected by GCA involving the aorta and its proximal branches. In this exhaustive review the authors assessed the qualitative and quantitative methods used for the assessment of vasculitis by 18-FDG-PET. They concluded that the qualitative methods may be more specific than semiquantitative ones, but they have lower sensitivity.
24. Gonzalez-Gay MA, Martinez-Dubois C, Agudo M, Pompei O, Blanco R, Llorca J. Giant cell arteritis: epidemiology, diagnosis, and management. Curr Rheumatol Rep. 2010;12:436–42.
25. Bejerano C, Blanco R, González-Vela C, Pérez-Martín I, Martinez-Rodriguez I, Jimenez-Bonilla J, et al. Polymyalgia rheumatica as presenting manifestation of vasculitis involving the lower extremities in a patient with ulcerative colitis. Clin Exp Rheumatol. 2012;30(1 Suppl 70):S110–3.
26. Bejerano C, Blanco R, González-Vela C, Agüero R, Carril JM, González-Gay MA. Refractory polymyalgia rheumatica as presenting manifestation of large-vessel vasculitis associated to sarcoidosis. Successful response to adalimumab. Clin Exp Rheumatol. 2012;30(1 Suppl 70):S94–7.
27. Martínez-Rodríguez I, Martínez-Amador N, Banzo I, Quirce R, Jiménez-Bonilla J, De Arcocha-Torres M, et al. Assessment of aortitis by semiquantitative analysis of 180-min (18)F-FDG PET/CT acquisition images. Eur J Nucl Med Mol Imaging. 2014;41(12):2319–24. Prospective study that included 43 consecutive patients assessed by semiquantitative analysis of PET-CT because of suspected large vessel vasculitis. The authors found that images acquired 180 min after 18 F-FDG injection and a target to background ratio index of 1.34 showed very high accuracy and are strongly recommended for the diagnosis of aortitis in the clinical setting.
28. Baerlecken NT, Linnemann A, Gross WL, Moosig F, Vazquez-Rodriguez TR, Gonzalez-Gay MA, et al. Association of ferritin autoantibodies with giant cell arteritis/polymyalgia rheumatica. Ann Rheum Dis. 2012;71:943–7. Ferritin autoantibodies may be useful as a diagnostic and activity marker of PMR and GCA.
29. Große K, Schmidt RE, Witte T, Baerlecken NT. Epitope mapping of antibodies against ferritin heavy chain in giant cell arteritis and polymyalgia rheumatica. Scand J Rheumatol. 2013;42:215–9. Potential diagnostic test for GCA and PMR can be improved by combining three human ferritin peptide antibodies.
30. Weyand CM, Goronzy JJ. Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;371:50–7. Review article that discussed preexisting information on the pathophysiology, diagnosis, clinical features and treatment of GCA. This review also points out some areas of uncertainty in GCA and PMR.
31. Figus M, Talarico R, Posarelli C, d’Ascanio A, Elefante E, Bombardieri S. Ocular involvement in giant cell arteritis. Clin Exp Rheumatol. 2013;31(1 Suppl 75):S96. Cohort study that confirms the high frequency of visual manifestations in patients with GCA. Early recognition and rapid onset of corticosteroid therapy is of main importance to prevent irreversible visual loss.
32. Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, Martínez-Taboada VM, Delgado-Rodriguez M, Figueroa M, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 1998;41:1497–504.
33. Muratore F, Pazzola G, Pipitone N, Boiardi L, Salvarani C. Large-vessel involvement in giant cell arteritis and polymyalgia rheumatica. Clin Exp Rheumatol. 2014;32(3 Suppl 82):S106–S11. An extremely interesting and informative review article that highlights important points on the diagnosis and management of patients with large vessel involvement in the setting of GCA.
34. Muratore F, Kermani TA, Crowson CS, Green AB, Salvarani C, Matteson EL, et al. Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford). 2014 Sep 5. pii: keu329. [Epub ahead of print] The clinical spectrum of patients with large vessel involvement in the setting of GCA is different from that found in patients presenting with typical cranial manifestations of GCA. Patients with large vessel involvement have less frequency of severe visual complication but they experience more relapses and have higher corticosteroid requirements than those presenting with classic cranial manifestations.
35. Talarico R, Boiardi L, Pipitone N, d'Ascanio A, Stagnaro C, Ferrari C, et al. Isolated aortitis versus giant cell arteritis: are they really two sides of the same coin? Clin Exp Rheumatol. 2014;32(3 Suppl 82):S55–8. An interesting study that confirms that the clinical spectrum of patients with isolated aortitis is different from that observed in those with cranial manifestations of GCA.
36. Salvarani C, Barozzi L, Boiardi L, Pipitone N, Bajocchi GL, Macchioni PL, et al. Lumbar interspinous bursitis in active polymyalgia rheumatica. Clin Exp Rheumatol. 2013;31:526–31. Inflammation of lumbar bursae may be responsible for the low back pain reported by patients with PMR.
37. Martinez-Lado L, Calviño-Díaz C, Piñeiro A, Dierssen T, Vazquez-Rodriguez TR, Miranda-Filloy JA, et al. Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine (Baltimore). 2011;90:186–93.
38. Alba MA, García-Martínez A, Prieto-González S, Tavera-Bahillo I, Corbera-Bellalta M, Planas-Rigol E, et al. Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine (Baltimore). 2014;93:194–201. Relapses are common in patients with GCA. They occur predominantly within the first 2 years of treatment. PMR symptoms are common with relapses but blindness is exceptional.
39. Lee JH, Choi ST, Kim JS, Yoon BY, Kwok SK, Kim HS, et al. Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR). Rheumatol Int. 2013;33:1475–80. As observed in GCA, relapses are also common in patients with PMR.
40. Yates M, Loke YK, Watts RA, MacGregor AJ. Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis. Clin Rheumatol. 2014;33:227–36. Randomized controlled trials on MTX or anti-TNF-alpha drugs versus corticosteroids do not show that the use of these adjunctive drugs may improve the outcome of GCA.
41. Mahr AD, Jover JA, Spiera RF, Hernández-García C, Fernández-Gutiérrez B, Lavalley MP, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56:2789–97.
42. Diamantopoulos AP, Hetland H, Myklebust G. Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series. Biomed Res Int. 2013;2013:120638. Small series of patients that showed a beneficial effect of leflunomide in GCA and PMR.
43. Loricera J, Blanco R, Castañeda S, Humbría A, Ortego-Centeno N, Narváez J, et al. Tocilizumab in refractory aortitis: study on 16 patients and literature review. Clin Exp Rheumatol. 2014;32(3 Suppl 82):S79. Tocilizumab may be effective in patients with inflammatory aortitis refractory to corticosteroids or to other biologic immunosuppressive drugs.
44. Macchioni P, Boiardi L, Catanoso M, Pulsatelli L, Pipitone N, Meliconi R, et al. Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature. Semin Arthritis Rheum. 2013;43:113–8. Tocilizumab has proved to be effective in some cases of PMR.
45. Gonzalez-Gay MA, Lopez-Diaz MJ, Martinez-Lado L, Peña-Sagredo JL, Lopez-Agreda H, Miranda-Filloy JA, et al. Cancer in biopsy-proven giant cell arteritis. A population-based study. Semin Arthritis Rheum. 2007;37:156–63.
46. Kermani TA, Schäfer VS, Crowson CS, Hunder GG, Gabriel SE, Ytterberg SR, et al. Malignancy risk in patients with giant cell arteritis: a population-based cohort study. Arthritis Care Res. 2010;62(2):149–54.
47. Ungprasert P, Sanguankeo A, Upala S, Knight EL. Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: A systematic review and meta-analysis. Semin Arthritis Rheum 2014 Jun 26. doi: 10.1016/j.semarthrit.2014.06.004. Overall, the risk of malignancy in GCA and PMR is not higher than in the general population.
48. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Gomez-Acebo I, Pego-Reigosa R, Lopez-Diaz MJ, Vazquez-Triñanes MC, et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine (Baltimore). 2009;88:227–35.
49. Tomasson G, Peloquin C, Mohammad A, Love TJ, Zhang Y, Choi HK, et al. Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study. Ann Intern Med. 2014;160:73–80. Unlike previous studies, a recent report suggests that cardiovascular disease may be increased in GCA.
50. Schmidt J, Kermani TA, Muratore F, Crowson CS, Matteson EL, Warrington KJ. Statin use in giant cell arteritis: a retrospective study. J Rheumatol. 2013;40:910–5. The use of statins may reduce the risk of GCA.